Show simple item record

 
dc.contributorHospital General de Granollers
dc.contributor.authorNogué Xarau, Santiago
dc.contributor.authorMartínez Sánchez, Lidia
dc.contributor.authorGarcia-Pelaez, Milagros
dc.contributor.authorPi Sala, Núria
dc.contributor.authorSALGADO, EMILIO
dc.contributor.authorFernández de Gamarra Martínez, Edurne
dc.contributor.authorGispert Ametller, Maria Angels
dc.contributor.authorAguilar Salmerón, Raquel
dc.date.accessioned2025-09-19T11:33:39Z
dc.date.available2025-09-19T11:33:39Z
dc.date.issued2025-08-19
dc.identifier.citationNogué-Xarau S, Martínez-Sánchez L, García-Peláez M, Fernández de Gamarra-Martínez E, Pi-Sala N, Gispert-Ametller À, et al. N-acetylcysteine: 50 years since the discovery of an antidote that has changed the prognosis of acetaminophen poisoning. Farm Hosp. 2025 Aug 19:S1130-6343(25)00109-6.
dc.identifier.issn1130-6343
dc.identifier.urihttp://hdl.handle.net/11351/13694
dc.descriptionAcetaminophen; Acetylcysteine; Liver toxicity
dc.description.abstractAcetaminophen is one of the most widely used drugs in clinical practice due to its analgesic and antipyretic properties. However, overdose is one of the leading causes of severe acute liver failure. N-acetylcysteine, introduced as an antidote in 1974, has revolutionized the management of this intoxication by reducing hepatotoxicity and mortality associated with acetaminophen toxicity. At the end of the 19th century, acetaminophen was identified as the main active metabolite of phenacetin and acetanilide. Its therapeutic use began to gain popularity in the 1950s and later became one of the main drugs involved in suicide attempts, particularly among adolescents and young adults. Acetaminophen-induced hepatotoxicity was first described in 1966, establishing that an overdose could lead to fulminant hepatic necrosis. In 1975, Rumack and Matthew published a nomogram that allowed stratification of hepatic toxicity risk based on plasma drug levels. The mechanism of hepatotoxicity was elucidated in the early 1970s when it was discovered that acetaminophen is metabolized by cytochrome P450 into a highly reactive intermediate, N-acetyl-p-benzoquinoneimine, which is normally neutralized by hepatic glutathione. In overdose situations, glutathione depletion leads to hepatic necrosis. Based on these findings, sulfhydryl-containing agents such as cysteamine and methionine were introduced as antidotes, but N-acetylcysteine ultimately proved to be the most effective treatment. Since its introduction, N-acetylcysteine administration protocols have evolved to optimize efficacy and minimize adverse effects. Protocols such as the Scottish and Newcastle Acetylcysteine Protocol and the Two Bags regimen have simplified dosing and reduced the incidence of anaphylactoid reactions. Over the past 50 years, N-acetylcysteine has saved thousands of lives and remains the gold-standard antidotal treatment for acetaminophen poisoning.
dc.language.isospa
dc.publisherElsevier
dc.relation.ispartofseriesFarmacia hospitalaria;
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectParacetamol
dc.subjectAcetilcisteïna
dc.subjectHepatotoxicitat
dc.subject.meshAcetylcysteine
dc.subject.meshAcetaminophen
dc.subject.meshLiver Failure, Acute
dc.titleN-acetylcysteine: 50 years since the discovery of an antidote that has changed the prognosis of acetaminophen poisoning
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.farma.2025.07.005
dc.subject.decsacetilcisteína
dc.subject.decsacetaminofén
dc.subject.decsfracaso hepático agudo
dc.relation.publishversionhttps://doi.org/10.1016/j.farma.2025.07.005
dc.type.versioninfo:eu-repo/semantics/acceptedVersion
dc.audienceProfessionals
dc.contributor.authoraffiliation[Nogué-Xarau S] Grup d’Antídots, Societat Catalana de Farmàcia Clínica, Barcelona, Spain. Fundación Española de Toxicología Clínica, Barcelona, Spain. [Martínez-Sánchez L] Grup d’Antídots, Societat Catalana de Farmàcia Clínica, Barcelona, Spain. Servei d’Urgències, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain. [García-Peláez M] Grup d’Antídots, Societat Catalana de Farmàcia Clínica, Barcelona, Spain. Fundación Española de Toxicología Clínica, Barcelona, Spain. Servei de Farmàcia, Hospital General de Granollers, Granollers, Spain. [Fernández de Gamarra-Martínez E] Grup d’Antídots, Societat Catalana de Farmàcia Clínica, Barcelona, Spain. Servei de Farmàcia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. [Pi-Sala N] Grup d’Antídots, Societat Catalana de Farmàcia Clínica, Barcelona, Spain. Servei de Farmàcia, Hospital de Figueres, Figueres, Spain. [Gispert-Ametller À] Grup d’Antídots, Societat Catalana de Farmàcia Clínica, Barcelona, Spain. Servei d’Urgències, Hospital Universitari Doctor Josep Trueta, Girona, Spain. [Salgado-García E] Grup d’Antídots, Societat Catalana de Farmàcia Clínica, Barcelona, Spain. Àrea d’Urgències, Hospital Clínic, Barcelona, Spain. [Aguilar-Salmerón R] Grup d’Antídots, Societat Catalana de Farmàcia Clínica, Barcelona, Spain. Servei de Farmàcia, Hospital Universitari Doctor Josep Trueta, Girona, Spain
dc.identifier.pmid40835518
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record